Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Bullboard Posts
Post by somweyungguyon Oct 05, 2016 10:57pm
218 Views
Post# 25315261

Ultimate choice of 176/180 was an educated decision...

Ultimate choice of 176/180 was an educated decision...We were led to believe that patients observed within the first 184 patients followed by a criteria change in April 2014 and fianlized in June 2014 could support or power the trial with a HUGE reduction in the required patient count.  This number suggested a minimum 20% absolute efficacy and the assumption that the expectation was even better and a higher number was chosen to cover the final absolute efficacy number.

The 5% makes little to NO CENTS, and we wonder why Dr.Spilker and the NR mention "within this sample size" on two seperate occasions.  Why was the 243 chosen to report on?  Why was the 18% NOT explained, WHY did Dr.Walker only speak to a "Bengarulian" that couldn't even accurately define us as a "medical device company"?  Something stinks, and I'm betting that a odour eater may arrive at sometime in the near future.  By rights the odour eater should return the shares to those that were spooked by a 5% number straight out of left field ( GO JAYS GO )

Sqr
Bullboard Posts